Westpac Banking Corp
WBC
CommBank
CBA
Fortescue Ltd
FMG
Rio Tinto Ltd
RIO
National Australia Bank Ltd
NAB
AU Stock MarketDetailed Quotes
ALA Arovella Therapeutics Ltd
- 0.175
- +0.005+2.94%
20min DelayMarket Closed Dec 27 16:00 AET
185.39MMarket Cap-19.44P/E (Static)
0.175High0.170Low113.09KVolume0.175Open0.170Pre Close19.55KTurnover0.21052wk High0.02%Turnover Ratio1.06BShares0.10552wk Low-0.009EPS TTM134.01MFloat Cap360.698Historical HighLossP/E (Static)765.74MShs Float0.020Historical Low-0.009EPS LYR2.94%Amplitude--Dividend TTM15.91P/B1Lot Size--Div YieldTTM
About Arovella Therapeutics Ltd Company
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Company Profile
SymbolALA
Company NameArovella Therapeutics Ltd
Founded1999
MarketASX
Employees14
Fiscal Year Ends06-30
Address84 Hotham Street Corporate One
CityPreston
CountryAustralia
Zip Code3072
Phone+61 398636472
Websitehttps://www.arovella.com
Share RegistryAUTOMIC REGISTRY SERVICES
477 Collins Street, MELBOURNE, VIC, AUSTRALIA, 3000
1300 288 664
Company Executives
- Name
- Position
- Salary
- Michael Baker
- Chief Executive Officer,Managing Director
- --
- Thomas (Tom) Duthy
- Non-Executive Chairman,Non-Executive Director
- --
- Gary Phillips
- Non-Executive Director
- --
- Elizabeth Stoner
- Non-Executive Director
- --
- Debora Barton
- Non-Executive Director
- --